Who We Are
At Kronos Bio, we’re focused on creating a world where no life is cut short by cancer or other serious diseases. That’s why we’re developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases—to bring forward novel therapies for patients who need them.
Our team has the tools, scientific expertise and determination to discover, develop and deliver medicines that reach traditionally hard-to-reach targets.
Transcription factors have long been attractive to drug developers, who historically have pursued them in isolation with little success. Our approach is different: We pursue the transcription factors in context, within their transcriptional regulatory networks (TRNs). By analyzing the TRN in its entirety, we can identify the critical nodes that are responsible for a transcription factor’s activity. This provides us with multiple avenues to pursue, rather than limiting our focus on a single transcription factor—and in turn, allows us to advance programs with the greatest potential to inhibit oncogenic activity.
We have three investigational compounds currently being evaluated for patients with cancer.
Our two investigational oral SYK inhibitors, entospletinib and lanraplenib, are being developed to treat acute myeloid leukemia (AML). SYK is a critical node in a dysregulated transcription regulatory network within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML. We are also advancing an oral CDK9 inhibitor, KB-0742, to treat patients with solid tumors addicted to oncogenic transcription factor activity. KB-0742 is the first investigational medicine from our internal discovery platform to enter the clinic. Beyond these three investigational compounds, we are progressing additional discovery programs, including one focused on the MYC TRN and another focused on the AR TRN. We continue to pursue earlier-stage discovery work across several additional TRNs.
Our work is our calling, and we’re pursuing it together.
Our team has an established track record with decades of scientific and business experience. We find meaning in making purposeful connections as we seek to bring forward groundbreaking therapies for patients who need them. We are intensely dedicated and curious—and we are taking informed risks to close the gaps between what we know now and what will change the way cancer and other serious diseases are treated in the future.
Our Core Values
Empower One Another
Embrace The Unknown
Turn Impossible Into Inevitable
Lead With Heart
Join our team.
We’re looking for individuals who want to join us as we seek to discover and develop new medicines. Our employees in San Mateo, California and Cambridge, Massachusetts are passionate about the scientific problems we’re striving to solve and the patients who could one day benefit from the progress we can make together.